ClariVest Asset Management LLC lowered its position in Amedisys Inc. (NASDAQ:AMED) by 5.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 52,922 shares of the company’s stock after selling 3,213 shares during the period. ClariVest Asset Management LLC’s holdings in Amedisys were worth $2,671,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of the company. Capstone Asset Management Co. increased its stake in Amedisys by 2.6% in the second quarter. Capstone Asset Management Co. now owns 8,929 shares of the company’s stock worth $451,000 after buying an additional 230 shares during the period. Aperio Group LLC increased its stake in Amedisys by 9.4% in the first quarter. Aperio Group LLC now owns 15,934 shares of the company’s stock worth $770,000 after buying an additional 1,363 shares during the period. Prudential Financial Inc. increased its stake in Amedisys by 2.8% in the first quarter. Prudential Financial Inc. now owns 75,959 shares of the company’s stock worth $3,672,000 after buying an additional 2,100 shares during the period. Acrospire Investment Management LLC acquired a new stake in Amedisys during the first quarter worth about $108,000. Finally, BNP Paribas Arbitrage SA increased its stake in Amedisys by 56.7% in the second quarter. BNP Paribas Arbitrage SA now owns 10,965 shares of the company’s stock worth $554,000 after buying an additional 3,966 shares during the period. 91.45% of the stock is owned by hedge funds and other institutional investors.
Amedisys Inc. (NASDAQ:AMED) traded up 2.74% during midday trading on Monday, hitting $46.88. The company had a trading volume of 174,737 shares. The company has a market cap of $1.57 billion, a P/E ratio of 41.01 and a beta of 0.96. The company’s 50 day moving average is $48.02 and its 200-day moving average is $49.82. Amedisys Inc. has a one year low of $31.16 and a one year high of $55.16.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported $0.42 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.42. The company had revenue of $360 million for the quarter, compared to the consensus estimate of $353.07 million. Amedisys had a return on equity of 12.17% and a net margin of 2.78%. The company’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.43 EPS. On average, equities analysts predict that Amedisys Inc. will post $1.69 EPS for the current year.
A number of research firms recently issued reports on AMED. Stephens began coverage on shares of Amedisys in a research report on Thursday, June 16th. They set an “equal weight” rating and a $55.00 target price for the company. Mizuho cut Amedisys from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $57.00 to $55.00 in a report on Wednesday, August 3rd. Jefferies Group restated a “buy” rating on shares of Amedisys in a report on Tuesday, September 6th. Zacks Investment Research upgraded Amedisys from a “sell” rating to a “hold” rating in a report on Thursday, August 4th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Amedisys in a report on Sunday, September 11th. Seven analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $51.75.
Amedisys Company Profile
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc. (NASDAQ:AMED).
Receive News & Ratings for Amedisys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.